Table 2.
Causes of early and late morbidity following lung TX in a randomized trial of FK506 vs. CsA
| Group | Mortality (≤30 days) | Cause of death (n) |
|---|---|---|
| Early | ||
| FK506 | 3% (1/38) | Toxoplasmosis (1) |
| CsA | 6% (2/36) | Bacterial pneumonia (1) |
| Cardiac arrest (1) | ||
| Late | ||
| FK506 | 13% (5/38) | P aeruginosa pneumonia (2) |
| Adenoviral pneumonia (2) | ||
| CMV pneumonia (1) | ||
| CsA | 16% (6/36) | P aeruginosa pneumonia (3) |
| Adenoviral pneumonia (1) | ||
| PTLD (1) | ||
| Respiratory failure (reason unknown) (1) | ||